Francisco J. Veiga-Gomez
Salamanca, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 04, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.
Journal: European urology
Published: July 14, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.
Journal: JAMA network open
Published: May 07, 2025
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 12, 2025
Focal therapy in prostate cancer and advances in the use of androgen blockade.
Journal: Frontiers in urology
Published: March 25, 2025
Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results.
Journal: Cancer medicine
Published: June 24, 2024
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).
Journal: European urology oncology
Published: October 30, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Journal: European urology oncology
Published: September 15, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Journal: European urology
Published: September 01, 2022
Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
Journal: European urology oncology
Published: May 18, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 14, 2022
Last Updated: 09/26/2026